Eli Lilly's modernisation plan cuts 250 jobs in France

The Fegersheim site will see a €100 million investment in new technology

picture of

Breaking News

Cell Mogrify undergoes period of change

A cash injection and change in leadership gives momentum to the cell therapy company for direct cellular conversion ...

Paris to host inaugural HealthTech Investor Day

In June, under the patronage of French President, Emmanuel Macron, France Biotech will play host to a gathering of ...

Helsinn invests €1 million in Gain Therapeutics

Swiss company will use the funding to address lysosomal storage disorders, CNS indications and additional diseases

Molecule: Pooling the pharma industry's resources

The new software platform from Linum Labs has been designed to crowdsource funding and research, in an effort to ...

Glenmark announces innovation spin-off company

In-principle approval has been given to turn the innovation division of the business into its own subsidiary in the US

Sosei Heptares announces €40 million Medicxi investment

Two asset-centric companies have been formed to develop Sosei’s novel therapies for neurological diseases funded by ...

A new way of buying and selling APIs, additives, vitamins and excipients

Swiss Kemiex and Atradius credit insurance launch unique commodity trading platform for the pharmaceutical and ...

Neuraxpharm expands into Central and Eastern Europe

The Spanish company has announced an expansion across Europe starting with the acquisition of Czech Republic-based ...

Hitachi buys all Acpeth Biopharma shares

Apceth Biopharma now becomes Hitachi's new European hub for cell therapy

Realising the potential of single-use technology

Today’s growing pipeline of biological drugs requires production environments that are agile and efficient

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27. ...

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is ...

Aslan cuts costs by 50% to compensate for failed drug trial

Asia’s pharma company has announced a restructure to cuts costs and refocus on remaining clinical programmes

Lonza reports CHF5.5 billion in sales in 2018

Full-year financials for the Swiss CDMO show 9% increase in organic sales